Palacaparib
Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer. It is a selective PARP1 inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375173256 under CC BY-SA 4.0; modifications have been made.